Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CUE stock hub

Cue Biopharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CUEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

113.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CUE

In the news

Latest news · CUE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-121.1

P25 -106.6P50 -46.9P75 -3.1

ROIC-58.2

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CUE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001645460
Company name	Cue Biopharma, Inc.
Country	United States
Country code	US
Cusip	22978P205
Employees	29
Employees Change	-12%
Employees Change Percent	-29.27
Enterprise value	$89.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2018-01-02
Isin	US22978P2056
Last refreshed	2026-05-10
Market cap	$113.9M
Market cap category	Micro-Cap
Price	$35
Price currency	USD
Rev Per Employee	947,103.45x
Sector	Healthcare
Sic	2834
Symbol	CUE
Website	https://www.cuebiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.35%
EV Sales Forward	8.9x
EV/Sales	3.27x
FCF yield	-19.19%
P/B ratio	4.26x
P/S ratio	4.15x
PS Forward	11.28x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-96.56%
EBITDA Margin	-93.07%
Gross margin	-26.86%
Gross Profit	$-7.4M
Net Income	$-26.6M
Net Income Growth Quarters	9%
Net Income Growth Years	3%
Pretax Margin	-95.03%
Profit Margin	-96.85%
Profit Per Employee	$-917,310
ROA	-44.56
Roa5y	-42.14
ROCE	-92.35
ROE	-121.1
Roe5y	-102.2
ROIC	-58.16

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	51.87%
Cagr3y	-37.97%
Cagr5y	-36.46%
EPS Growth Quarters	12
EPS Growth Years	3
Revenue Growth	195.75x
Revenue Growth Q	1,292.26x
Revenue Growth Quarters	1x
Revenue Growth Years	3x
Revenue Growth3 Y	180.46x
Revenue Growth5 Y	54.16x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.74
Assets	$42.2M
Cash	$28.2M
Current Assets	$37M
Current Liabilities	$13.5M
Debt	$4.2M
Debt Equity	$0.16
Equity	$26.4M
Interest Coverage	-74.29
Liabilities	$15.8M
Long Term Assets	$5.2M
Long Term Liabilities	$2.3M
Net Cash	$24M
Net Cash By Market Cap	$21.09
Net Cash Growth	65.6%
Net Debt Equity	$-0.91
Tangible Book Value	$26.4M
Tangible Book Value Per Share	$8.21
WACC	17

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.74
Net Working Capital	$-2.8M
Quick ratio	2.64
Working Capital	$23.5M
Working Capital Turnover	$1.57

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-68.18%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	51.83%
200-day SMA	16.82
3Y total return	-76.14%
50-day SMA	13.74
50-day SMA vs 200-day SMA	50under200
5Y total return	-89.64%
All Time High	950.7
All Time High Change	-96.32%
All Time High Date	2020-05-26
All Time Low	4.97
All Time Low Change	604.08%
All Time Low Date	2026-04-06
ATR	6.01
Beta	2.39
Beta1y	4.48
Beta2y	2.81
Ch YTD	282
High	36.98
High52	41.42
High52 Date	2026-05-06
High52ch	-15.5%
Low	34.01
Low52	4.97
Low52 Date	2026-04-06
Low52ch	604.08%
Ma50ch	154.75%
Premarket Change Percent	-1.85
Premarket Price	$35.07
Premarket Volume	1,525
Price vs 200-day SMA	108.04%
RSI	70.7
RSI Monthly	48.58
RSI Weekly	76.87
Sharpe ratio	0.93x
Sortino ratio	2.34
Total Return	-68.18%
Tr YTD	282
Tr1m	519.91%
Tr1w	15.06%
Tr3m	264.47%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.11
Earnings Revenue Estimate	1,000,000x
Earnings Revenue Estimate Growth	137.53x
Operating Income	$-26.5M
Operating margin	-96.56
Price target	$120
Price Target Change	$243

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,908,172%
Float Percent	89.33%
Net Borrowing	-4,500,000
Shares Insiders	10.67%
Shares Institutions	22.37%
Shares Out	3,255,359
Shares Qo Q	9.56%
Shares Yo Y	68.18%
Short Ratio	0.34

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-26.6M
Average Volume	1,472,488.4x
Bv Per Share	8.21
CAPEX	$-177,000
Ch1m	519.9
Ch1w	15.06
Ch1y	51.83
Ch3m	264.5
Ch3y	-76.14
Ch5y	-89.64
Ch6m	66.38
Change	-2.04%
Change From Open	-0.99
Close	35.73
Days Gap	-1.06
Depreciation Amortization	958,000
Dollar Volume	8,550,325
Earnings Date	2026-05-13
Earnings Time	amc
EBIT	$-26.5M
EBITDA	$-25.6M
EPS	$-8.42
F Score	4
FCF	$-21.9M
FCF EV Yield	-24.32x
FCF Per Share	$-6.72
Financing CF	26,291,000
Fiscal Year End	December
Founded	2,014
Income Tax	$500,000
Investing CF	75,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-16
Last Report Date	2025-12-31
Last Split Date	2026-04-24
Last Split Type	Reverse
Last10k Filing Date	2026-03-16
Ma150	14.65
Ma150ch	138.96%
Ma20	22.05
Ma20ch	58.72%
Net CF	4,679,000
Next Earnings Date	2026-05-22
Open	35.35
Optionable	Yes
Position In Range	33.33
Post Close	35
Postmarket Change Percent	-1.29
Postmarket Price	$34.55
Ppne	4,315,000
Pre Close	35.73
Price Date	2026-05-08
Ptbv Ratio	4.31
Relative Volume	0.17x
Revenue	27,466,000x
SBC By Revenue	17.27x
Share Based Comp	4,744,000
Tax By Revenue	1.82x
Tr6m	66.38%
Us State	Massachusetts
Volume	244,295
Z Score	-10.72

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CUE pay a dividend?

Capital-return profile for this ticker.

Performance

CUE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CUE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+22.4%

Float: +89.3% of shares outstanding

Insider ownership

+10.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CUE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

70.7

Above 70: short-term overbought

Price vs 200-day MA

+108.0%

50/200-day relationship not available

Beta (5Y)

2.39

More volatile than the market

Sharpe ratio

0.93

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CUE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CUE stock rating?

Cue Biopharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CUE analysis?

The full report lives at /stocks/CUE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CUE?

The latest report frames CUE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CUE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.